|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 8280 WILLOW OAKS CORPORATE DRIVE |
Address2 | SUITE 500 |
City | FAIRFAX |
State | VA |
Zip Code | 22031 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 57737-12
|
||||||||
|
6. House ID# 352510000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Laura Thevenot, Chief Executive Officer |
Date | 01/21/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
SConRes 70 / HConRes 321, S 3230 (Labor-HHS Appropriations) regarding the appropriations allocation for the National Institutes of Health (NIH) and the National Cancer Institute (NCI); allocation for the implementation of the Nurse Reinvestment Act and other nursing workforce development programs at the Health Resources and Service Administration (HRSA); funding for the Dept. of Energy's nuclear medicine research and medical applications program
HR 2642 (Supplemental Appropriations Act of 2008) and the economic stimulus legislation (American Recovery and Reinvestment Act) regarding increased funding for NIH and NCI
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Emily |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Support for legislation to reform health care through a combination of public and private approaches to cover medically necessary services
HR 6791 (National Cancer Fund Act of 2008) to increase federal taxes on tobacco products and dedicate these revenues to increase cancer research funding
HR 3014 (Health Equity and Accountability Act of 2007) to expand culturally and linguistically appropriate health care service and to address racial and ethnic disparities
Anticipated legislation from Senators Kennedy and Hutchinson to address the unique cancer needs of patients and to renew and revive programs to cure cancer
Encourging President-elect Obama to appoint highly qualified individuals to key positions such as the Secretary of HHS, Commissioner of FDA, and Director of NIH
S. 2999/HR 2676 (Access to Cancer Clinical Trials Act of 2007) to amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to require group and individual health insurance coverage and group health plans to provide coverage for individuals participating in approved cancer clinical trials.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Richard |
Martin |
Esq |
|
|
Emily |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 6331 (Medicare Improvements for Patients and Providers Act of 2008) to stabilize Medicare physician payments
S 2785 (Save Medicare Act of 2008) to stabilize Medicare physician payments
HR 2749 / S 1519 (Voluntary Medicare Quality Reporting Act of 2007) to evaluate the Physician Quality Reporting Initiative
HR 1078 (Comprehensive Cancer Care Improvement Act of 2007) to expand cancer care planning, comprehensive symptom management and to authorize demonstrations for hospice and palliative care for cancer patients
S 2029 (Physicians Payment Sunshine Act of 2007) to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP
HR 583 / S 1042 (Consistency Accuracy Responsibility in Medical Imaging and Radiation Therapy Act of 2007) to establish standards for personnel who perform, plan, evaluate, or verify patient dose for medical imaging studies and radiation therapy treatments
Encourage President Bush to consider an executive order to remove radiation therapy from the "in-office ancillary" services list of designated health services.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dave |
Adler |
|
|
|
Emily |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
To protect access to medical isotopes used in cancer treatments such as brachytherapy and stereotactic radiosurgery
HR 5624 (Radiological Materials Security Act) to review and increase secure measures of radiologic materials that could be used in a radiologic dispersal device
HR 6816 (Nuclear Facility and Materials Security Act of 2008) reagrding provisions related to the use of cesium chloride
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Nuclear Regulatory Commission (NRC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Martin |
Esq |
|
|
Emily |
Wilson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |